Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.

The market may consolidate further and take cues from the RBI policy for further direction. Below are some trading ideas for ...

Another seasonal trend is the four-year U.S. presidential cycle. In general, the market rises modestly in the first year after a presidential election, followed by trouble in the second year. In years ...

China's BYD is set to unveil driver-assist tech for the masses. Shares are soaring. Tesla stock is at a 2025 low.

Skyworks Solutions' stock plummeted more than 24% Thursday after the analogue chipmaker projected a slowdown in its mobile ...

In my daily analysis of US indices, the NASDAQ 100 is always the first place I checked. <li /> This is mainly due to the fact that it ha ...

The USD/JPY currency pair has been under selling pressure, dropping to a two-month low of 151.80 before stabilizing around 152.60 at the ...

Amgen posted strong earnings beat and has an attractive dividend, and technical chart forecasting positive future performance ...

A dip in Roblox's daily active users sparked growth concerns on Wall Street and sent the stock plunging as much as 20% on ...

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

The Nasdaq shows signs of uncertainty, with price action indicating a potential slowdown amid trade war concerns. See why I ...

The Chart of the Week looks at Morningstar's stock valuations for the Australian market and how it compares to the past.